Yumanity Therapeutics, Inc.

NasdaqCM:YMTX Stock Report

Market Cap: US$143.6m

Yumanity Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: YMTX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of YMTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders950,5778.76%
Private Companies1,184,56110.9%
Institutions2,392,72422%
General Public6,328,62558.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.

Top Shareholders

Top 25 shareholders own 41.7% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15%
FMR LLC
1,628,470US$21.5m0.09%no data
10.9%
Susan L. Lindquist Family Trust
1,184,561US$15.7m0%no data
6.85%
N. Coles
743,677US$9.8m0%no data
2.42%
The Vanguard Group, Inc.
262,343US$3.5m-7.94%no data
2%
Artal Group S.A.
217,391US$2.9m0%0.02%
0.63%
Renaissance Technologies LLC
68,722US$909.2k-2.53%no data
0.55%
Richard Peters
59,557US$787.9k-15.5%no data
0.51%
Geode Capital Management, LLC
55,533US$734.7k0%no data
0.49%
Paulash Mohsen
52,818US$698.8k0%no data
0.46%
Citadel Advisors LLC
49,543US$655.4k190%no data
0.4%
BlackRock, Inc.
43,185US$571.3k0%no data
0.21%
Susquehanna International Group, LLP, Asset Management Arm
22,556US$298.4k12.3%no data
0.15%
Meenu Chhabra
16,070US$212.6k0%no data
0.14%
Millennium Management LLC
15,387US$203.6k-81.9%no data
0.13%
Michael Wyzga
13,997US$185.2k-18.2%no data
0.13%
Devin Smith
13,961US$184.7k-18.3%no data
0.12%
Jeffery Kelly
13,154US$174.0k0%no data
0.11%
Acadian Asset Management LLC
11,831US$156.5k-57.9%no data
0.1%
Verus Capital Partners, Llc
11,216US$148.4k0.01%no data
0.082%
Marie Epstein
8,883US$117.5k-18.2%no data
0.075%
Cecil Pickett
8,117US$107.4k0%no data
0.075%
Richard Heyman
8,117US$107.4k0%no data
0.073%
Marija Zecevic
7,879US$104.2k0%no data
0.056%
BG Fund Management Luxembourg S.A.
6,117US$80.9k0%no data
0.04%
David Arkowitz
4,347US$57.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/19 06:37
End of Day Share Price 2022/12/16 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yumanity Therapeutics, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Michael YeeJefferies LLC
Kelechi ChikereJefferies LLC